<DOC>
	<DOC>NCT01760343</DOC>
	<brief_summary>A new formulation of Berinert (CSL830) is being investigated for the management of hereditary angioedema (HAE). The main aim of the study is to assess the safety of a single 1500 IU dose of the new formulation of Berinert. This study will also look at the pharmacokinetics of CSL830 relative to Berinert currently on the market.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas, Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I and II</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Healthy subjects without clinically significant medical conditions or laboratory abnormalities Male or female subjects aged 18 to 45 years inclusive, at the time of informed consent Nonsmokers Body mass index of 18.0 to 29.0 kg/m2 inclusive Previous history of clinically significant arterial or venous thrombosis, current history of a clinically significant prothrombotic risk, or a clinically significant abnormality on laboratory thrombotic screen at the screening visit. Known or suspected hypersensitivity to the investigational medicinal product (IMP), or to any excipients of the IMP. Female subjects who started taking or changed dose of any hormonal contraceptive regimen or hormone replacement therapy (ie, estrogen/progesterone containing products) within 3 months before the screening visit. Alcohol, drug, or medication abuse within one year before the study. Female subjects of childbearing potential (eg, not postmenopausal) either not using, or not willing to use, a medically reliable method of contraception for the entire duration of the study, or have a vasectomized partner, or not sexually abstinent for the entire duration of the study, or not surgically sterile. Participation in another clinical study (or use of another IMP) within 30 days (or 5 times the halflife, whichever is longer) before, or during, the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>